Detalles de la búsqueda
1.
Thrombopoietin receptor agonist discontinuation rates and reasons among patients with immune thrombocytopenia: a study of administrative claims linked with medical chart review.
Ann Hematol
; 101(9): 1915-1924, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35849155
2.
Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel.
Acta Haematol
; 144(4): 418-426, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33789275
3.
Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study.
Ann Hematol
; 99(4): 743-752, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32065291
4.
Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study.
Br J Haematol
; 185(1): 102-106, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30592022
5.
Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.
Am J Hematol
; 94(2): 200-208, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30417939
6.
Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial.
Br J Haematol
; 181(5): 628-636, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29774521
7.
A Discrete Choice Experiment to Elicit Patient Willingness to Pay for Attributes of Treatment-Induced Symptom Relief in Comorbid. Insomnia.
Manag Care
; 24(4): 42-8, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26489177
8.
Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States.
Am J Cardiovasc Drugs
; 23(2): 197-206, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36780092
9.
Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and/or receiving tafamidis prescriptions: A retrospective analysis of a Medicare cohort.
J Manag Care Spec Pharm
; 28(7): 766-777, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35737856
10.
Temporal Trends in Diagnostic Testing Patterns for Wild-Type Transthyretin Amyloid Cardiomyopathy in the Medicare Fee-for-Service Population.
Am J Cardiol
; 167: 98-103, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35022130
11.
Baseline Characteristics and Secondary Medication Adherence Patterns Among Patients Receiving Tafamidis Prescriptions: A Retrospective Analysis Using a National Specialty Pharmacy Dispensing Database.
Patient Prefer Adherence
; 16: 1115-1129, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35517043
12.
The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
Clin Ther
; 42(5): 860-872.e8, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32199608
13.
Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists.
J Comp Eff Res
; 9(7): 447-457, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32175766
14.
A framework for planning and critiquing medication compliance and persistence research using prospective study designs.
Clin Ther
; 31(2): 421-35, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19302915
15.
Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States.
Clinicoecon Outcomes Res
; 11: 673-681, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31814747
16.
Medication compliance and persistence: terminology and definitions.
Value Health
; 11(1): 44-7, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18237359
17.
Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia.
Clinicoecon Outcomes Res
; 10: 715-721, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30464564
18.
A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists.
J Comp Eff Res
; 7(8): 775-784, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29848048
19.
Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
Expert Rev Hematol
; 10(10): 933-939, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28885063
20.
Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.
Appl Health Econ Health Policy
; 15(1): 45-55, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27550239